(A) Kaplan-Meier estimates of the probability of survival in 55 patients who received an allogeneic stem cell transplant for AMM. The 5-year probability of overall survival was 47% for the overall group, 54% for patients receiving an unmanipulated HLA matched related transplant, and 26% for those receiving a T-cell–depleted graft or a graft coming from an alternative donor (P = .18). (B) Outcome according to the severity of myelofibrosis (MF) before transplant. The 5-year probability of survival was 55% if there was grade I or II marrow fibrosis, and 38% if there was grade III marrow fibrosis (osteomyelosclerosis) (P = .027). (C) Outcome according to the score proposed by Dupriez et al before transplant. The 5-year probability of survival was 83% for the patients in the low-risk group, 43% for the patients in the intermediate-risk group, and 31% for the patients in the high-risk group (P = .018). (D) Outcome according to the hemoglobin level at transplant and the requirement of RBC transfusions before transplant. The 5-year probability of survival was 76% for patients with hemoglobin level >100 g/L or with hemoglobin level ≤100 g/L and no RBC transfusion before transplant, and 23% for patients with hemoglobin level ≤100 g/L receiving pretransplant RBC transfusions (P < .0001).